Patents Represented by Attorney, Agent or Law Firm Timothy E. Torchia
  • Patent number: 6280732
    Abstract: The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 28, 2001
    Assignee: Genentech, Inc.
    Inventors: Ingrid W. Caras, John W. Winslow
  • Patent number: 6037320
    Abstract: A novel polypeptide, designated neurotrophic factor-4 (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. Also provided herein are nucleic acids encoding naturally occurring amino acid sequence variants of NT-4, designated NT-4.beta., NT-4.gamma., and NT-4.DELTA.. The neurotrophic factors of the invention are useful in the treatment of nerve cells and in diagnostic assays.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: March 14, 2000
    Assignee: Genentech, Inc.
    Inventor: Arnon Rosenthal
  • Patent number: 6027927
    Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobin sequences.
    Type: Grant
    Filed: October 1, 1997
    Date of Patent: February 22, 2000
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
  • Patent number: 6025166
    Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns imnunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: February 15, 2000
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
  • Patent number: 6005081
    Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: December 21, 1999
    Assignee: Genentech, Inc.
    Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
  • Patent number: 5981480
    Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: November 9, 1999
    Assignee: Genentech, Inc.
    Inventors: Roman Urfer, Leonard G. Presta, John W. Winslow
  • Patent number: 5980894
    Abstract: The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.
    Type: Grant
    Filed: April 10, 1997
    Date of Patent: November 9, 1999
    Assignee: Genentech, Inc.
    Inventor: Kyung Jin Kim
  • Patent number: 5910574
    Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: June 8, 1999
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
  • Patent number: 5877016
    Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns inmunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: March 2, 1999
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
  • Patent number: 5853978
    Abstract: Diagnostic product and vaccine for Acquired Immuno-deficiency Syndrome (AIDS) and methods for making and using same, wherein viral polypeptide sequences from an AIDS associated retrovirus are expressed directly or as a fusion polypeptide in a prokaryotic or mammalian cell expression host to produce a diagnostic product which specifically binds complementary antibody produced by individuals afflicted with AIDS or a vaccine against AIDS which confers resistance to infection by AIDS associated retrovirus. The reverse transcriptase of an AIDS associated retrovirus is used separately or in a whole cell assay to identify compounds which selectively inhibit retroviral reverse transcriptase.
    Type: Grant
    Filed: July 29, 1994
    Date of Patent: December 29, 1998
    Assignee: Genentech, Inc.
    Inventors: Phillip W. Berman, Daniel J. Capon, Laurence A. Lasky
  • Patent number: 5849533
    Abstract: Methods for making unclipped HIV env proteins are provided. According to the methods, a genetically engineered cell line comprising an nucleic acid sequence encoding an HIV env protein is cultured to produce unclipped HIV env protein, which is recovered from the cell culture.
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: December 15, 1998
    Assignee: Genetech, Inc.
    Inventors: Phillip W. Berman, Brian M. Fendly, Timothy J. Gregory, Elorian M. Wurm
  • Patent number: 5844092
    Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: December 1, 1998
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
  • Patent number: 5837241
    Abstract: A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.
    Type: Grant
    Filed: July 26, 1996
    Date of Patent: November 17, 1998
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Kathleen King, Elizabeth Luis, Jennie P. Mather, Nicholas F. Paoni
  • Patent number: 5830858
    Abstract: A novel polypeptide, designated neurotrophic factor-4 (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. Also provided herein are nucleic acids encoding naturally occurring amino acid sequence variants of NT-4, designated NT-4.beta. and NT-4.gamma.. The neurotrophic factors of the invention are useful in the treatment of nerve cells and in diagnostic assays.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: November 3, 1998
    Assignee: Genentech, Inc.
    Inventor: Arnon Rosenthal
  • Patent number: 5804557
    Abstract: Methods and compositions for excipient stabilization of dry or aqueous polypeptides treated with organic solvents are disclosed, wherein the polypeptide is admixed with a polyol having a molecular weight less than about 70,000 kD.
    Type: Grant
    Filed: September 24, 1996
    Date of Patent: September 8, 1998
    Assignee: Genentech, Inc.
    Inventors: Jeffrey L. Cleland, Andrew J. S. Jones
  • Patent number: 5798448
    Abstract: The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: August 25, 1998
    Assignee: Genentech, Inc.
    Inventors: Ingrid W. Caras, John W. Winslow
  • Patent number: 5759775
    Abstract: Provided are nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders. The present invention provides methods to preferentially detect or amplify AL-1 nucleic acid in a sample using AL-1 nucleotide sequence probes.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: June 2, 1998
    Assignee: Genetech, Inc.
    Inventors: Ingrid W. Caras, John W. Winslow
  • Patent number: 5753219
    Abstract: Methods and compositions for excipient stabilization of dry or aqueous polypeptides treated with organic solvents are disclosed, wherein the polypeptide is admixed with a polyol having a molecular weight less than about 70,000 kD.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: May 19, 1998
    Assignee: Genentech, Inc.
    Inventors: Jeffrey L. Cleland, Andrew J. S. Jones
  • Patent number: 5728803
    Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: March 17, 1998
    Assignee: Genentech, Inc.
    Inventors: Roman Urfer, Leonard G. Presta, John W. Winslow
  • Patent number: 5723585
    Abstract: Isolated CHF, isolated DNA encoding CHF, recombinant or synthetic methods of preparing CHF, and a method of purifying CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: March 3, 1998
    Assignee: Genentech, Inc.
    Inventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood